Exploring Autophagy in Cancer: Therapeutic Perspectives

Authors

  • Dr. Anand Mohan Jha Post Graduate Department of Chemistry, M. L. S. M. College, Darbhanga, (Lalit Narayan Mithila University, Darbhanga, Bihar)
  • Dr. Anil Kumar Post Graduate Department of Chemistry, Sahibganj College, Sahibganj (S. K. M. University, Dumka, Jharkhand)
  • Dr. Kumud Kumari Department of Psychology, MLSM College, Darbhanga (Lalit Narayan Mithila University, Darbhanga, Bihar)
  • Dr. Rashmi Hosamani Associate Professor, Department of Microbiology, Tumkur University, Karnataka
  • Dr. S. Ravichandran Professor and Head in Chemistry, DRK Institute of Science and Technology, Bowrampet, Hyderabad-500043.
  • Dr. Vanitha Innocent Rani Assistant professor, Department of community & Psychiatric Nursing, Faculty of Nursing, King Khalid University, Mahayil, Asir Region, KSA.
  • Dr Priyanka Singh Additional Professor, Department of Oral Pathology and Microbiology, Faculty of Dental Sciences, King George's Medical University, Lucknow

DOI:

https://doi.org/10.22376/ijtos.2024.2.4.1-6

Keywords:

Autophagy,, Cancer, Tumor Suppression, Chemo resistance, Therapeutic Target, Hydroxychloroquine

Abstract

Autophagy is a catabolic mechanism crucial for sustaining cellular homeostasis, and in this process, encapsulated degraded inside repurposed to facilitate metabolic processes. In cancer, autophagy has a dual role: it acts as a tumor suppressor by preventing the buildup of damaged cellular components, but also as a survival mechanism, that supports tumor growth under stress. Cancer cells often trigger autophagy to manage the increased metabolic demands of rapid growth. This stress tolerance allows tumor cells to maintain energy production, contributing to both tumor progression and resistance to treatment. Preclinical studies have shown that autophagy inhibition reinstates chemotherapeutic sensitivity and increases tumor cell mortality. These findings indicate that targeting autophagy may represent a viable therapeutic approach, with early-phase clinical trials exploring the use of hydroxychloroquine alongside chemotherapy or targeted treatments. As comprehension of autophagy in oncology advances, there is an increasing interest in creating more targeted and efficacious autophagy inhibitors for therapeutic applications.

References

Ryter SW, Cloonan SM, Choi AM. Autophagy: a critical regulator of cellular metabolism and homeostasis. Molecules and cells. 2013 Jul 1;36(1):7-16.

Tai H, Wang Z, Gong H, Han X, Zhou J, Wang X, Wei X, Ding Y, Huang N, Qin J, Zhang J. Autophagy impairment with lysosomal and mitochondrial dysfunction is an important characteristic of oxidative stress-induced senescence. Autophagy. 2017 Jan 2;13(1):99-113.

Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003;112:1809–20.

Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and selfkilling: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007;8:741–52.

Duffy A, Le J, Sausville E, Emadi A. Autophagy modulation: a target for cancer treatment development. Cancer chemotherapy and pharmacology. 2015 Mar;75:439-47.

Li W, Zhang L. Regulation of ATG and autophagy initiation. Autophagy: Biology and Diseases: Basic Science. 2019:41-65.

Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282:24131–45.

Ng EL, Gan BQ, Ng F, Tang BL. Rab GTPases regulating receptor trafficking at the late endosome–lysosome membranes. Cell biochemistry and function. 2012 Aug;30(6):515-23.

Ballesteros‐Álvarez J, Andersen JK. mTORC2: The other mTOR in autophagy regulation. Aging cell. 2021 Aug;20(8):e13431.

Karabi Z, Moradian F, Kheirabadi M. The effect of lactoferrin on ULK1 and ATG13 genes expression in breast cancer cell line MCF7 and bioinformatics studies of protein interaction between lactoferrin and the autophagy initiation complex. Cell Biochemistry and Biophysics. 2022 Dec;80(4):795-806.

Tian W, Li W, Chen Y, Yan Z, Huang X, Zhuang H, Zhong W, Chen Y, Wu W, Lin C, Chen H. Phosphorylation of ULK1 by AMPK regulates translocation of ULK1 to mitochondria and mitophagy. FEBS letters. 2015 Jul 8;589(15):1847-54.

Papandreou I, Lim AL, Laderoute K, Denko NC. Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death & Differentiation. 2008 Oct;15(10):1572-81.

Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proceedings of the National Academy of Sciences. 2003 Dec 9;100(25):15077-82.

Wang Y, Zhang N, Zhang L, Li R, Fu W, Ma K, Li X, Wang L, Wang J, Zhang H, Gu W. Autophagy regulates chromatin ubiquitination in DNA damage response through elimination of SQSTM1/p62. Molecular cell. 2016 Jul 7;63(1):34-48.

Divya T, Sureshkumar A, Sudhandiran G. Autophagy induction by celastrol augments protection against bleomycin-induced experimental pulmonary fibrosis in rats: Role of adaptor protein p62/SQSTM1. Pulmonary Pharmacology & Therapeutics. 2017 Aug 1;45:47-61.

Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh III HJ, Lotze MT. Endogenous HMGB1 regulates autophagy. Journal of Cell Biology. 2010 Sep 6;190(5):881-92.

Ying H, Qu D, Liu C, Ying T, Lv J, Jin S, Xu H. Chemoresistance is associated with Beclin-1 and PTEN expression in epithelial ovarian cancers. Oncology letters. 2015 Apr 1;9(4):1759-63.

Heras-Sandoval D, Pérez-Rojas JM, Hernández-Damián J, Pedraza-Chaverri J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cellular signalling. 2014 Dec 1;26(12):2694-701.

Zhao Y, Chen G, Zhang W, Xu N, Zhu JY, Jia J, Sun ZJ, Wang YN, Zhao YF. Autophagy regulates hypoxia‐induced osteoclastogenesis through the HIF‐1α/BNIP3 signaling pathway. Journal of cellular physiology. 2012 Feb;227(2):639-48.

RASHMI BA, HARISHCHANDER A, SIVARAMAN T. AN OUTLOOK ON DRUGGABLE TARGETS TO COMBAT PANCREATIC DUCTALADENOCARCINOMA. SPECIAL ISSUE ON.:98.

Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, Debnath J. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Molecular biology of the cell. 2011 Jan 15;22(2):165-78.

Larsson LG. Oncogene-and tumor suppressor gene-mediated suppression of cellular senescence. InSeminars in cancer biology 2011 Dec 1 (Vol. 21, No. 6, pp. 367-376). Academic Press.

Wong PM, Puente C, Ganley IG, Jiang X. The ULK1 complex: sensing nutrient signals for autophagy activation. Autophagy. 2013 Feb 28;9(2):124-37.

Kanzawa T, Zhang L, Xiao L, Germano IM, Kondo Y, Kondo S. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene. 2005 Feb;24(6):980-91.

Banga R, Banga V, Eltalla A, Shahin L, Parag S, Naim M, Iyer E, Kumrah N, Zacharias B, Nathanson L, Beljanski V. Effects of autophagy modulators tamoxifen and chloroquine on the expression profiles of long non-coding RNAs in MIAMI cells exposed to IFNγ. Plos one. 2022 Apr 21;17(4):e0266179.

Wu L, Feng Z, Cui S, Hou K, Tang L, Zhou J, Cai G, Xie Y, Hong Q, Fu B, Chen X. Rapamycin upregulates autophagy by inhibiting the mTOR-ULK1 pathway, resulting in reduced podocyte injury. PloS one. 2013 May 8;8(5):e63799.

Alves CL, Ditzel HJ. Drugging the PI3K/AKT/mTOR pathway in ER+ breast cancer. International Journal of Molecular Sciences. 2023 Feb 24;24(5):4522.

Maity A, Cerniglia GJ, Karar J, Koumenis C. Inhibition of autophagy as a strategy to augment radiosensitization by the dual PI3K/mTOR inhibitor NVP-BEZ235. International Journal of Radiation Oncology, Biology, Physics. 2012 Nov 1;84(3):S127.

Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, Jahreiss L, Fleming A, Pask D, Goldsmith P, O'kane CJ. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nature chemical biology. 2008 May;4(5):295-305.

Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs of today (Barcelona, Spain: 1998). 2005 Feb 1;41(2):107-27.

Harada M, Sakisaka S, Yoshitake M, Kin M, Ohishi M, Shakado S, Mimura Y, Noguchi K, Sata M, Tanikawa K. Bafilomycin A1, a specific inhibitor of vacuolar-type H+-ATPases, inhibits the receptor-mediated endocytosis of asialoglycoproteins in isolated rat hepatocytes. Journal of hepatology. 1996 May 1;24(5):594-603.

Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene. 2012 Mar;31(13):1661-72.

Edwards J. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert opinion on investigational drugs. 2010 May 1;19(5):605-14.

Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, McAfee Q. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014 Aug 20;10(8):1359-68.

Kim SH, Kwon D, Lee S, Ki SH, Jeong HG, Hong JT, Lee YH, Jung YS. Polyhexamethyleneguanidine phosphate-induced cytotoxicity in liver cells is alleviated by tauroursodeoxycholic acid (TUDCA) via a reduction in endoplasmic reticulum stress. Cells. 2019 Sep 3;8(9):1023.

Jung KT, Oh SH. Polyubiquitination of p62/SQSTM1 is a prerequisite for Fas/CD95 aggregation to promote caspase-dependent apoptosis in cadmium-exposed mouse monocyte RAW264. 7 cells. Scientific Reports. 2019 Aug 22;9(1):12240.

Amin S, Lux A, O'Callaghan F. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. British journal of clinical pharmacology. 2019 Jan;85(1):37-46.

Koehl GE, Spitzner M, Ousingsawat J, Schreiber R, Geissler EK, Kunzelmann K. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APCMin/+ mice. Oncogene. 2010 Mar;29(10):1553-60.

Published

01-10-2024

How to Cite

Jha, D. A. M., D. A. Kumar, D. K. Kumari, D. R. Hosamani, D. S. Ravichandran, D. V. Innocent Rani, and D. P. Singh. “Exploring Autophagy in Cancer: Therapeutic Perspectives”. International Journal of Trends in OncoScience, vol. 2, no. 4, Oct. 2024, pp. 1-6, doi:10.22376/ijtos.2024.2.4.1-6.

Issue

Section

Review Articles